ABSTRACT: Hyaluronan (HA) has been shown to play crucial roles in the tumorigenicity of malignant tumors. Chondrosarcoma, particularly when low-grade, is characterized by the formation of an extracellular matrix (ECM) containing abundant HA, and its drug/radiation resistance has become a clinically relevant problem. This study aimed to evaluate the effects of an HA synthesis inhibitor, 4-methylumbelliferone (MU), on ECM formation as well as antitumor effects in chondrosarcoma. We investigated the effects of MU on rat chondrosarcoma (RCS) cells with a grade I histological malignancy in vitro and in vivo grafted model. HA binding protein (HABP) stainability on and around the RCS cells was effectively reduced with treatment of MU. ECM formation was markedly suppressed by MU at a dose of 1.0 mM. Cell proliferation was significantly reduced by MU at 24 h. Cell motility and invasion were suppressed in a dose-dependent manner by MU. No significant changes in mRNA expression of Has1À3 were observed. Furthermore, MU inhibited the growth of grafted tumors in vivo. Histologically, chondrosarcoma cells of control tumors showed a cell-clustering structure. HABP stainability was markedly decreased in the MU-treated group. These results suggest that MU exhibits antitumor effects on low-grade chondrosarcoma, via inhibition of HA accumulation and ECM formation. MU, which is an approved drug in bile therapy, could be a new off-label medication for chondrosarcomas. ß
Chondrosarcoma is the second most common primary malignant bone tumor and is characterized by the production of a cartilaginous matrix by malignant cells. 1, 2 Histological grading is important in chondrosarcoma and has been shown to be useful in predicting clinical behavior and prognosis. 3 The majority of these tumors grow slowly and rarely metastasize, although more aggressive, high grade forms have also been observed. 4 Chondrosarcoma is generally considered to be relatively chemo-and radiotherapy resistant, with such resistance being a serious issue in its clinical management, particularly in unresectable cases. 5 Wide surgical excision has been established as the best therapeutic modality; however, there is no treatment for unresectable or metastatic tumors. 4, 5 Several hypotheses have been postulated to explain primary resistance in conventional chondrosarcoma. The extracellular matrix (ECM) containing abundant HA has been considered as one explanation of resistance, especially in low-grade chondrosarcoma. 1 Hyaluronan (HA) is a high molecular-weight linear glycosaminoglycan, the structure of which comprises repeating disaccharides of D-glucuronic acid and N-acetyl-D-glucosamine. HA is a ubiquitous extracellular and cell surface-associated matrix component of connective, epithelial, and neural tissues. 6 Increased HA levels are also observed in the stroma of malignant areas and in part of the tumor parenchyma in some malignant tumors, including colorectal, ovarian, and breast cancer, and osteosarcoma. [7] [8] [9] [10] Several studies have shown that HA levels correlate with the proliferation, motility, invasion, and metastasis of malignant tumor cells. [11] [12] [13] [14] This may occur partly because an increased HA-rich matrix may support invasion by providing cancer cells with a suitable microenvironment, 15 stimulate cell motility via interactions of HA with cell-surface receptors, and/or form a barrier for cancer cells against hostimmunocompetent cells.
14 Moreover, increased pericellular HA levels may lead to drug resistance against anticancer agents. Therefore, inhibition of HA synthesis can be considered as a therapeutic tool against chondrosarcoma.
A 4-Methylumbelliferone (MU) is a cholagogue that is widely used as an oral medicine. 16 It is also known to inhibit HA synthesis via glucuronidation by endogenous glucuronosyltransferase (UGT), which results in the depletion of uridine diphosphate glucuronic acid (UDP-GlcUA). 17 Several studies have documented the anticancer effects of MU through HA synthesis inhibition in vitro and in vivo with or without anticancer agents. [18] [19] [20] [21] However, no study has investigated the inhibitory effects of MU on chondrosarcoma, which has HA rich ECM.
In this study, we hypothesized that inhibition of HA synthesis by MU in rat chondrosarcoma (RCS) cells with an HA-rich ECM might alter ECM formation and suppress tumorigenicity. This study aimed to evaluate the effects of an HA synthesis inhibitor on ECM formation as well as its antitumor effects on RCS cells in vitro and tissues in vivo.
MATERIALS AND METHODS

Cell Line
The cell line used in our study was established from transplantable swarm RCS cells with a grade I histological malignancy and has been maintained in continuous monolayer culture for a number of years. 22 This long-term cultured cell line (LTC-RCS) has been used as a model system for analyzing chondrocyte metabolism and could be used for chondrosarcoma study with low grade malignancy.
Cell Cultures RCS cells were grown in a humidified atmosphere at 37˚C with 5% CO2 in DMEM medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 mg/ ml streptomycin. RCS cells were grown in an identical medium. MU stock solution for vitro experiments was dissolved in Dimethylsulfoxide (DMSO), and the final concentration of DMSO in medium was adjusted to 1.0%. All incubations are performed in the presence of 10% FBS.
HA Staining for Cells and Tissues
HA accumulation in RCS cells in vitro and the grafted tumor in vivo were visualized using biotinylated hyaluronic acid binding protein (b-HABP; Seikagaku, Tokyo, Japan) as described previously. 23 The cells were seeded into chamber slides (BD Biosciences, Franklin Lakes, NJ) for 24 h, followed by treatment with or without 0.1-1.0 mM MU for 24 h to determine MU effects on HA accumulation. Cultured RCS cells were fixed with 4% paraformaldehyde buffered with PBS at room temperature for 2 h. The tissue sections of grafted tumor were pretreated with 1 U/ml Chondroitinase ABC (pH 8.0) for 1 h at 37˚C. The cells in the chamber slides and tumor tissue sections of the in vivo model were subjected to incubation with 2.0 mg/ml b-HABP probe for 2 h at room temperature. Bound b-HABP was detected by the addition of streptavidin-peroxidase reagents (Nichirei, Tokyo, Japan) and diamino-benzidine-containing substrate solution (Nichirei).
Preparation of Glycosaminoglycans and HA Quantification RCS cells (10 5 cells each) were incubated with (1.0 mM MU) or without MU (0.1% DMSO) for 24 h. HA was isolated according to previously described methods. 24 Briefly, the conditioned medium was collected and designated as "medium." To extract the cell-surface associated HA, the cells were incubated for 10 min at 37˚C with trypsin-EDTA and washed with PBS. The trypsin solution and combined washes were designated as "pericellular." After cell counting, the cells were placed in Proteinase K solution (0.15 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.01 M CaCl2, and 5 mM deferoxamine mesylate containing 20 U of proteinase K) and incubated for 2 h at 55˚C, and this solution was designated as "intracellular." All samples were heated at 100˚C for 15 min to inactivate protease activity and centrifuged at 15,000g for 30 min at 4˚C, after which the supernatants were subjected to the analyses.
To analyze the amount of HA in the grafted tumor, the tumor from each rat were placed in a test tube, frozen in liquid nitrogen, crushed to powder with mT-12 beads crusher (TAITEC Corp., Saitama, Japan) following manufacturer's instruction. The powder in a test tube was suspended in 600 ml of 0.2N NaOH and then incubated overnight at room temperature. After neutralization with 1N HCl, the solutions were adjusted to contain 0.15M Tris, 0.15M NaCl, 0.01M CaCl2, 5 mM deferoxamine mesylate, and 20 U/ml protease E at pH8, and further incubated at 55˚C for 8 h. After inactivation of protease E by heating at 95˚C for 15 min, the solutions were centrifuged at 12,000 rpm for 10 min to remove insoluble materials. The supernatants were mixed with three volumes of 95% ethanol containing 1.3% of potassium acetate, incubated at À20˚C for 30 min, and then centrifuged at 12,000 rpm for 10 min at 4˚C. The pellets were washed once with cold 70% ethanol and then dissolved in PBS. Prepared solutions from in vitro or in vivo samples were subjected to HA quantification. The HA concentrations were measured using a competitive ELISA, as described previously. 25 Visualization of Functional Cell-Associated Coat Functional cell-associated matrix was visualized and evaluated as previously described 26 after 24 h culture with or without 0.1-0.4 mM MU. To give a coat to cell ratio, a matrix area was defined as the area delineated by the cell associated matrix minus the area delineated by the plasma membrane (defined as cell area). 27 Cell Viability Assay RCS cells were seeded in 96-well plates at 1 Â 10 4 /well in medium containing 10% FBS and allowed to adhere for 6 h. The subconfluent cells were exposed to 10% FBS medium with or without DMSO containing 0.1-1.0 mM MU. After 24, 48, and 72 h of treatment, cell proliferation was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5,diphenyl tetrazolium bromide (MTT) colorimetric assay with Cell proliferation Kit I (Roche Diagnostics, Mannheim, Germany).
Motility and Matrigel Invasion Assays
The chemotactic motility of RCS cells was investigated using 12-well cell culture chambers containing inserts with 12-mm pores (Millipore, Billerica, MA). Invasion of RCS cells was assayed in the same chambers that contained inserts with 12-mm pore membrane coated with matrigel. The cells were added to the upper chamber at a density of 5 Â 10 4 cells per insert in the presence or absence of 0.1-1.0 mM MU, and a chemotaxis buffer was added to the lower chamber. After 24 h of incubation, cells on the upper surface were wiped off with a cotton swab. Cells that had invaded the lower surface were fixed with 70% ethanol and stained with hematoxylin. Cells from 10 different fields were counted under a light microscope at Â400 magnification.
Real-Time RT-PCR Analysis
Expression levels of Has1, Has2, and Has3 were determined in RCS cells after treatment with or without 0.1-1.0 mM MU for 12 h. Total cellular RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. Following conventional reverse transcriptase-polymerase chain reaction (RT-PCR), cDNA was subjected to real time RT-PCR for semi-quantification of Has1, Has2, and Has3 mRNAs using a LightCycler (Roche Diagnostics). The relative levels of Has1, Has2, and Has3 mRNA in a sample were expressed as relative quantification normalized with expression levels of Gapdh mRNA. 
Analysis of Grafted Tumor
Swarm RCS cells are derived from a tumor that originally arose spontaneously in a female Sprague-Dawley (SD) rat. This tumor grows locally in the subcutaneous tissue and does not metastasize, indicating low-grade malignancy. 28 A cell suspension (5 Â 10 6 cells in 100 ml PBS) of RCS cells was carefully injected into subcutaneous tissue in SD rats (8-weeks-old, 260-280 g, five rats each group). After confirmation of tumor development at 4 weeks, the mice were randomly divided into two groups, a control group and a group treated with MU. Five hundred ml of 0.4% carboxymethyl cellulose sodium (CMC) solution (control: 0.4% CMC solution only) with or without MU (100 mg per rat) was administered daily to each rat intraperitoneally for 10 weeks. The resultant tumor was surgically excised at 10 weeks after continuous MU treatment. The tumor was totally resected under general anesthesia with an intraperitoneal injection of pentobarbital. Total volume was calculated weekly with a formula of p/6 (length (cm)) Â (width (cm)) Â (height (cm)). After 10 weeks' treatment, totally excised tumor was weighed. Excised tumors were evaluated histologically with H-E staining, and HA accumulation was analyzed with HABP staining. The experimental protocol was approved by the Animal Care Committee of our institution and the experiments were performed according to the principles outlined in the US National Academy of Sciences' Guide for the Care and Use of Laboratory Animals. All rats were housed in a temperature and humidity controlled environment under 12 h light/12 h dark cycle and fed a standard rodent diet.
Statistical Analysis
All the quantitative experiments in vitro were performed more than three times. Analysis of variance, followed by the Bonferroni-Dunn post hoc test, was used to assess differences between means. Statistical comparison between two groups in vivo was achieved using a Mann-Whitney U test.
RESULTS
Effects of MU on HA Accumulation and Cell-Associated Matrix Formation in RCS Cells
Cells treated with the control medium for 24 h showed dark staining in cytoplasms and cell surfaces for HA (Fig 1A) . In contrast, cells treated with 0.1 or 1.0 mM MU for 24 h showed substantial inhibition of HA positive staining (Fig. 1B and C, respectively) . One of the functions of surface-retained hyaluronan is to serve as a scaffold for the assembly of cell-associated matrices. 29, 30 On tumor cells, such matrices may favor tumor cell motility or help to shield the tumor cells from immunocompetent cells. 11, 14 Cell-associated matrices can be visualized around live RCS cells by use of a particle exclusion assay. Tumor cells in the control medium displayed abundant cell-associated matrices after 24 h of culture. However, MU treatment resulted in a substantial decrease in the area of cell-associated matrices (Fig 2A) in a dose-dependent manner (Fig 2B) . The proportion of pericellular matrix area in RCS cells treated with 1.0 mM MU was significantly lower than that in the control cells.
At the 24 h time points of cell culture, treatment with 1.0 mM MU significantly suppressed the amount of pericellular and intracellular HA in RCS cells (Fig. 1D , E, p ¼ 0.0495, for each). However, the amount of HA in medium was not significantly changed (Fig. 1F) .
Effects of MU on Cell Growth in RCS Cells
MU inhibited RCS cell proliferation in a dosedependent manner at each time point (Fig. 3) . Cell growth in RCS cells with 0.4 and 1.0 mM MU was significantly inhibited compared with controls at 24-h (0.4 mM: 25.5% reduction, p ¼ 0.017; 1.0 mM: 27.1% reduction, p ¼ 0.006). Treatment with 0.1, 0.4 and 1.0 mM MU exhibited the inhibitory effect at 48 h (29.4%, 39.1%, and 38.1% inhibition, respectively) and 72 h (33.5%, 53.2%, and 56.4% inhibition, respectively) (p < 0.01, for each dose)
Effects of MU on Cell Migration and Invasiveness of RCS Cells
The migration activity of RCS cells treated with MU for 24 h was significantly lower in a dose dependent manner than that with control medium (Fig. 4A) . The migrating activity of cells treated with 0.1 and 1.0 mM MU was significantly reduced compared with that of control cells (31.9%; p ¼ 0.024 and 66.4%; p < 0.01, respectively). The ability of the RCS cells to pass though the matrigelcoated filters was significantly reduced when treated with 1.0 mM MU (66.5%) than when treated with control culture (p < 0.01), whereas that of RCS cells treated with 0.1 mM MU tended to be lower than that with control culture (21.7%, p ¼ 0.052, Fig. 4B ).
Effects of MU on mRNA Expression of HA Synthesizing Enzymes
Because MU inhibits HA synthesis, mRNA expression levels of HA synthesizing enzyme (Has1, 2, and 3) might be altered after treatment with MU. Results of RT-PCR showed that MU treatment tended to increase Has1, 2, and 3 expression, although the difference did not reach statistical significance at 12 h (Fig. 5) .
MU Had Inhibitory Effects on Local Tumor Growth
Low-grade chondrosarcoma rarely metastasizes; however, local tumor growth impairs patients' QOL.
Results of in vivo experiments demonstrated that daily administration of MU markedly inhibited local tumor growth. From week 7-10 ( Fig. 6A) , increase of tumor volume was significantly inhibited with daily treatment of MU (100 mg/body). At 10 weeks', tumor weight was also significantly reduced with treatment with MU (p ¼ 0.043, Fig. 6B ). Chondrosarcoma cells of control groups formed more cell-clustering like structures (Fig. 7A , arrows) compared with MU group (Fig. 7B) . On HABP staining an HABP positive area was prominently observed in the extracellular matrix of control tumor (Fig. 7C ) compared with that of MU treated tumor (Fig. 7D) . As shown in Figure 7E , the MU treatment significantly suppressed the amount of HA in grafted tumor (p < 0.01). HA is known to be distributed ubiquitously in the body. Although depletion of HA could affect the physiological structure of HA-abundant tissues, the administration of MU did not affect the structure of skin or body weight in this in vivo experiment.
DISCUSSION
The majority of conventional chondrosarcomas, which are of low or intermediate grade malignant potential, grow slowly, and rarely metastasize. These tumors are usually curable with surgical resection, including curettage for grade I tumors or en bloc resection with wide margin for grade 2-3 tumors. A good outcome is expected after complete resection of the tumors. However, the treatment of unresectable tumor is challenging due to the lack of an effective therapeutic approach other than surgery. Conventional chemotherapy has proven to be largely ineffective with the exception of a potential role in mesenchymal and dedifferentiated subtypes. 31 Because progression of low-grade tumors is slow but steady, a novel therapeutic tool is required particularly for unresectable low-grade tumors.
RCS cells exhibit characteristics similar to those of cell-associated matrices as articular chondrocytes, which exhibit large, HA-rich cell-associated matrix. 26, 29 Several previous studies have reported that HA plays crucial roles in the maintenance of ECM integrity in articular cartilage. Given that structural features of HA-rich ECM in low-grade sarcoma are similar to those in articular cartilage, alteration of the ECM structure in low-grade chondrosarcoma may affect the tumorigenicity of the cells and tumorous tissues. We hypothesized that inhibition of HA accumulation by MU in RCS cells might decrease cellassociated matrix formation, and subsequently affect the tumorigenicity of these cells. The results of this study supported the hypothesis that MU inhibits HA accumulation and cell-associated matrix formation, and exerts anti-tumor effects. Several studies have implicated HA-rich ECM in the tumorigenicity of malignant cells, particularly in osteosarcoma, with suppression of this HA-rich ECM leading to inhibition of malignant cell behavior. 27, 32, 33 However, abundant HA-rich ECM is more characteristic for low-grade chondrosarcoma than for osteosarcoma, and no previous studies have investigated the significance of HArich ECM in chondrosarcoma. Moreover, no experiments manipulating the ECM formation in chondrosarcoma have been conducted previously. The cartilaginous nature of ECM and poor vascularity of chondrosarcoma cells may also impede the diffusion of drugs and their access to tumor cells. 5, 34 Suzuki et al. 32 demonstrated that suppression of pericellular matrix formation may improve the drug uptake into the cells. ECM suppression by MU treatment may thus improve the drug sensitivity of chondrosarcoma.
The mechanisms underlying the anti-tumor effects of MU have been speculated about in several previous studies. HA has been reported to promote migration. 35, 36 Because MU inhibits HA synthesis via depletion of uridine diphosphate glucuronic acid (UDP-GlcUA), 17 suppressed HA by MU may have blocked cell motility and invasion of chondrosarcoma cells in the present study. Kultti et al showed that mRNA expression levels of HAS2 or HAS3, or both, were reduced in a dose-dependent manner by MU in all the cancer cell lines (melanoma, breast cancer, ovarian cancer, squamous cell carcinoma) studied. 37 Previous reports have described that suppresion of HAS2 mRNA by antisense technique reduces cell motility 27 transcriptional repression at the HAS genes by MU, which may be another possible anti-tumor mechanism. However, in the present study, expression levels of Has1-3 mRNA were increased, but not significantly so, with MU treatment, in line with previous findings indicating that HAS gene expression is upregulated by MU in osteosarcoma cells. 18 Alteration of HAS mRNA expression by MU would be cell type-dependent, differing for instance between epithelial tumor and mesenchymal tumor cells. Proliferation of chondrosarcoma cells was also inhibited by MU. Suppression of HA-rich ECM by MU would also inhibit the tumorous behavior of chondrosarcoma cells. Forced expression of versican, which is a large chondroitin sulfate proteoglycan with important roles in maintaining HA-rich cell-associated matrix, induced a marked increase in cell-associated matrix, and enhanced cell motility and migration. 38 Results of in vivo grafted model revealed that inhibitory effects of MU were more prominent than those of in vitro experiments. Arai et al. 18 reported that HA retention in the surrounding stromal tissues and perivascular lesions with MU treatment was lower than that in the control of osteosarcoma in vivo model. Marked inhibitory effects of MU in the present study may be explained that not only tumor cell itself, also microenvironment of tumor stroma and surrounding normal cells (pericytes, vascular endothelial cells, and fibroblasts), which affect tumorigenicity, can be influenced by MU.
There were several limitations in this study. First, interactions with the HA-cell surface receptor, such as CD44, were not evaluated. Endogenous HA-CD44 interactions are known to influence the activity of several signaling pathway components. Previous studies have shown that the PI3K/Akt signaling pathway is significantly involved in HA-induced cell motility and invasiveness. 19 Block of these pathways by MU may cause inhibitory activity. Second, we did not investigate whether MU could enhance the drug sensitivity of low-grade chondrosarcoma mediated by inhibition of cell-associated matrix formation. This is an important issue considering that MU treatment alone does not completely suppress RCS cells as reported in other studies. 18, 19 Studies on the synergistic effects of MU with chemotherapeutic agents or radiotherapy need to be analyzed in greater detail. Third, the dose of MU used for the rat in this study was approximately 300-350 mg/kg/day, which has been considered to be a safe dose. 39 However, the optimal dose to attain anti-tumor effects in man remains to be established.
In conclusion, we showed that low-grade chondrosarcoma, which is chemo-and radio-resistant tumor, was effectively suppressed by MU, an HA synthesis inhibitor, both in vitro and in vivo. Given that MU has already been used clinically as an oral choleretic agent, and has been judged to be nontoxic, MU may be a novel and useful antitumor agent for the treatment of low-grade chondrosarcoma.
